Literature DB >> 23999180

Congenital heart conditions: Patent foramen ovale closure--not all devices are equal.

Bernhard Meier1.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23999180     DOI： 10.1038/nrcardio.2013.136

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  10 in total

1.  Improvement of migraine headaches after percutaneous closure of patent foramen ovale for secondary prevention of paradoxical embolism.

Authors:  Andreas Wahl; Fabien Praz; Tony Tai; Oliver Findling; Nazan Walpoth; Krassen Nedeltchev; Markus Schwerzmann; Stephan Windecker; Heinrich P Mattle; Bernhard Meier
Journal:  Heart       Date:  2010-06       Impact factor: 5.994

2.  Nonoperative closure of atrial septal defects.

Authors:  T D King; N L Mills
Journal:  Surgery       Date:  1974-03       Impact factor: 3.982

3.  Long-term propensity score-matched comparison of percutaneous closure of patent foramen ovale with medical treatment after paradoxical embolism.

Authors:  Andreas Wahl; Peter Jüni; Marie-Luise Mono; Bindu Kalesan; Fabien Praz; Laura Geister; Lorenz Räber; Krassen Nedeltchev; Heinrich P Mattle; Stephan Windecker; Bernhard Meier
Journal:  Circulation       Date:  2012-01-11       Impact factor: 29.690

4.  Closure or medical therapy for cryptogenic stroke with patent foramen ovale.

Authors:  Anthony J Furlan; Mark Reisman; Joseph Massaro; Laura Mauri; Harold Adams; Gregory W Albers; Robert Felberg; Howard Herrmann; Saibal Kar; Michael Landzberg; Albert Raizner; Lawrence Wechsler
Journal:  N Engl J Med       Date:  2012-03-15       Impact factor: 91.245

Review 5.  Transcatheter closure of patent foramen ovale after presumed paradoxical embolism.

Authors:  N D Bridges; W Hellenbrand; L Latson; J Filiano; J W Newburger; J E Lock
Journal:  Circulation       Date:  1992-12       Impact factor: 29.690

6.  Percutaneous device closure of patent foramen ovale for secondary stroke prevention: a call for completion of randomized clinical trials: a science advisory from the American Heart Association/American Stroke Association and the American College of Cardiology Foundation.

Authors:  Patrick T O'Gara; Steven R Messe; E Murat Tuzcu; Gloria Catha; John C Ring
Journal:  Circulation       Date:  2009-05-11       Impact factor: 29.690

Review 7.  Patent foramen ovale transcatheter closure vs. medical therapy on recurrent vascular events: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Pablo Rengifo-Moreno; Igor F Palacios; Parichart Junpaparp; Christian F Witzke; D Lynn Morris; Abel Romero-Corral
Journal:  Eur Heart J       Date:  2013-07-11       Impact factor: 29.983

8.  Long-term results of a randomized trial comparing three different devices for percutaneous closure of a patent foramen ovale.

Authors:  Marius Hornung; Stefan C Bertog; Jennifer Franke; Dani Id; Margaret Taaffe; Nina Wunderlich; Laura Vaskelyte; Ilona Hofmann; Horst Sievert
Journal:  Eur Heart J       Date:  2013-07-09       Impact factor: 29.983

9.  Closure of patent foramen ovale versus medical therapy after cryptogenic stroke.

Authors:  John D Carroll; Jeffrey L Saver; David E Thaler; Richard W Smalling; Scott Berry; Lee A MacDonald; David S Marks; David L Tirschwell
Journal:  N Engl J Med       Date:  2013-03-21       Impact factor: 91.245

10.  Percutaneous closure of patent foramen ovale in cryptogenic embolism.

Authors:  Bernhard Meier; Bindu Kalesan; Heinrich P Mattle; Ahmed A Khattab; David Hildick-Smith; Dariusz Dudek; Grethe Andersen; Reda Ibrahim; Gerhard Schuler; Antony S Walton; Andreas Wahl; Stephan Windecker; Peter Jüni
Journal:  N Engl J Med       Date:  2013-03-21       Impact factor: 91.245
  10 in total
  1 in total

1.  Effectiveness and Safety of Transcatheter Patent Foramen Ovale Closure for Migraine (EASTFORM) Trial.

Authors:  Ying-Qi Xing; Yu-Zhu Guo; Yong-Sheng Gao; Zhen-Ni Guo; Peng-Peng Niu; Yi Yang
Journal:  Sci Rep       Date:  2016-12-14       Impact factor: 4.379
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.